Piper Sandler analyst Jason Bednar upgraded Becton Dickinson (BDX – Research Report) to a Buy today and set a price target of $290.00. The company’s shares closed yesterday at $251.57. According to TipRanks, Bednar is an analyst with an average return of -4.7% and a 39.43% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Masimo, Align Tech, and Becton Dickinson. In addition to Piper Sandler, Becton Dickinson also received a Buy from Barclays’s Matt Miksic in a report issued on May 8. However, on May 5, Citi maintained a Hold rating on Becton Dickinson (NYSE: BDX). See the top stocks recommended by analysts >> The company has a one-year high of $266.70  and a one-year low of $214.27. Currently, Becton Dickinson has an average volume of 1.04M.
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Founded in 1897, Becton, Dickinson & Co. is a New Jersey-based medical technology company. The company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional.  Read More on BDX: Indices Commodities Currencies Stocks